Edition:
United States

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

162.09USD
23 Feb 2018
Change (% chg)

$2.69 (+1.69%)
Prev Close
$159.40
Open
$161.53
Day's High
$162.50
Day's Low
$160.05
Volume
808,104
Avg. Vol
715,298
52-wk High
$256.78
52-wk Low
$156.00

Select another date:

Thu, Feb 22 2018

BRIEF-FDA Acceptance Of Medicines360's Filing For Supplemental NDA For Liletta 52 Mg

* FDA ACCEPTANCE OF MEDICINES360'S FILING FOR SUPPLEMENTAL NEW DRUG APPLICATION FOR LILETTA® (LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM) 52 MG Source text for Eikon: Further company coverage:

BRIEF-Molecular Partners' Partner Allergan Exercises Third Option For Darpin Product Candidate In Ophthalmology

* MOLECULAR PARTNERS' PARTNER ALLERGAN EXERCISES THIRD OPTION FOR DARPIN PRODUCT CANDIDATE IN OPHTHALMOLOGY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Allergan Files For Potential Mixed Shelf Offering

* ALLERGAN PLC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING Source text: (http://bit.ly/2EvYOO0) Further company coverage:

BRIEF-Appaloosa Dissolves Share Stake In GM & Whirlpool, Ups Stake In Allergan

* APPALOOSA LP DISSOLVES SHARE STAKE IN GENERAL MOTORS CO - SEC FILING

BRIEF-Allergan Declares Q1 2018 Cash Dividend Of $0.72 Per Share

* ALLERGAN DECLARES FIRST QUARTER 2018 CASH DIVIDEND OF $0.72 PER ORDINARY SHARE AND PROVIDES ANNUAL GENERAL MEETING OF SHAREHOLDERS UPDATES Source text for Eikon: Further company coverage:

Allergan's profit beats; migraine drug succeeds in key study

Allergan Plc on Tuesday reported better-than-expected quarterly profit on robust demand for Botox, boosted its earnings forecast and announced positive data on one of the two migraine treatments it is developing.

UPDATE 3-Allergan's profit beats; migraine drug succeeds in key study

Feb 6 Allergan Plc on Tuesday reported better-than-expected quarterly profit on robust demand for Botox, boosted its earnings forecast and announced positive data on one of the two migraine treatments it is developing.

BRIEF-Allergan Reports Q4 Non-GAAP Earnings Per Share $4.86

* ALLERGAN REPORTS SOLID FINISH TO 2017 WITH 12% INCREASE IN FOURTH QUARTER GAAP NET REVENUES TO $4.3 BILLION

Allergan posts quarterly profit; migraine treatment succeeds key study

Feb 6 Allergan Plc posted a quarterly profit, compared with a year-ago loss, due to recent changes in the U.S. tax laws, and the botox maker said its migraine treatment met the main goals in a late-stage study.

BRIEF-Allergan Announces Positive Phase 3 Results For Ubrogepant

* ALLERGAN ANNOUNCES POSITIVE TOP LINE PHASE 3 RESULTS FOR UBROGEPANT - AN ORAL CGRP RECEPTOR ANTAGONIST FOR THE ACUTE TREATMENT OF MIGRAINE

Select another date: